These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
47. Association between in vitro platinum resistance in the EDR assay and clinical outcomes for ovarian cancer patients. Holloway RW; Mehta RS; Finkler NJ; Li KT; McLaren CE; Parker RJ; Fruehauf JP Gynecol Oncol; 2002 Oct; 87(1):8-16. PubMed ID: 12468336 [TBL] [Abstract][Full Text] [Related]
53. Treatment of recurrent ovarian cancer: a retrospective analysis of women treated with single-agent carboplatin originally treated with carboplatin and paclitaxel. The Memorial Sloan-Kettering Cancer Center experience. Dizon DS; Dupont J; Anderson S; Sabbatini P; Hummer A; Aghajanian C; Spriggs D Gynecol Oncol; 2003 Dec; 91(3):584-90. PubMed ID: 14675681 [TBL] [Abstract][Full Text] [Related]
54. Chemotherapy in advanced ovarian carcinoma: current standards of care based on randomized trials. Thigpen T; Vance R; Puneky L; Khansur T Gynecol Oncol; 1994 Dec; 55(3 Pt 2):S97-107. PubMed ID: 7835816 [TBL] [Abstract][Full Text] [Related]
55. [Docetaxel and ovarian cancer]. Ray-Coquard I Bull Cancer; 2004 Feb; 91(2):159-65. PubMed ID: 15047455 [TBL] [Abstract][Full Text] [Related]